Delos Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Delos Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1	Closed	-$772	–	299
2025 Q4	$772	Hold	1	–	–	﹤0.01%	250
2025 Q3	$563	Hold	1	–	–	﹤0.01%	277
2025 Q2	$525	Buy	+1	New	+$558	﹤0.01%	257
2024 Q3	–	Sell	-6	Closed	-$6.31K	–	326
2024 Q2	$6.31K	Hold	6	–	–	0.01%	146
2024 Q1	$5.78K	Buy	6 +4	+200%	+$3.8K	0.01%	153
2023 Q4	$1.76K	Sell	2 -52	-96%	-$42.8K	﹤0.01%	141
2023 Q3	$44.6K	Hold	54	–	–	0.05%	75
2023 Q2	$38.8K	Hold	54	–	–	0.05%	73
2023 Q1	$44.4K	Hold	54	–	–	0.06%	67
2022 Q4	$39K	Hold	54	–	–	0.06%	67
2022 Q3	$37K	Buy	54 +2	+4%	+$1.26K	0.04%	62
2022 Q2	$31K	Hold	52	–	–	0.03%	70
2022 Q1	$36K	Hold	52	–	–	0.04%	80
2021 Q4	$33K	Buy	+52	New	+$32K	0.03%	99

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Delos Wealth Advisors's REGN Position: Q1 2026 in Review

Delos Wealth Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 1 share — an estimated $772 sold.

Delos Wealth Advisors first reported a position in REGN in Q4 2021 and held it in 14 quarters. The position peaked at $44.6K in Q3 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Delos Wealth Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Delos Wealth Advisors sold 1 Regeneron Pharmaceuticals share in Q1 2026, an estimated $772.
Delos Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 14 quarters.
Delos Wealth Advisors's Regeneron Pharmaceuticals position peaked at $44.6K in Q3 2023.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Delos Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.